ATECTURA® is the commercial brand name of Indacaterol Acetate and Mometasone Furoate Powder for Inhalation (Ⅱ), a fixed‑dose combination containing long‑acting beta₂ agonist and inhaled corticosteroid developed by Novartis. Indacaterol acetate relaxes bronchial smooth muscle; mometasone furoate provides potent anti‑inflammatory action in the respiratory tract.
Main Indications
For the maintenance treatment of asthma in adult patients who need combined therapy with an inhaled corticosteroid and a long‑acting beta₂ agonist.
Clinical Research
Pivotal phase III studies demonstrated that this once‑daily fixed combination significantly improved lung function and lowered asthma exacerbation rates compared with individual monocomponents. The safety profile supported long‑term maintenance treatment.
Common Side Effects
Oropharyngeal candidiasis, nasopharyngitis, headache, dysphonia;
Other common reactions: palpitations, upper respiratory tract infection. Rare serious adverse events include paradoxical bronchospasm and severe hypersensitivity reactions.
Approval Status in China
Original drug ATECTURA® (Indacaterol Acetate and Mometasone Furoate Powder for Inhalation (Ⅱ)) was officially approved for marketing in China in 2024, with the specification of 150/160 μg. Each package includes 30 capsules and one Breezhaler inhaler. It is currently a prescription drug.
Buy ATECTURA (Indacaterol Acetate and Mometasone Furoate Powder for Inhalation (Ⅱ)) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
